{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Maine's innovative effort to reduce prescription drug costs for uninsured state residents by pressuring manufacturers to grant price rebates received the Supreme Court's qualified approval today. The 6-to-3 decision lifted an injunction that has kept the Maine Rx Program from taking effect since the state's Legislature enacted it in 2000. The court's action is likely to shift the drug pricing debate away from the courts and back to the executive branch and the states.", "headline": {"main": "Justices Allow Drug-Cost Plan To Go Forward", "kicker": "THE SUPREME COURT: THE RULING"}, "abstract": "Supreme Court gives qualified approval to Maine's innovative effort to reduce prescription drug costs for uninsured state residents; 6-to-3 decision lifts injunction that has kept Maine Rx Program from taking effect since state's Legislature enacted it in 2000; decision is likely to shift drug pricing debate away from courts and back to executive branch and states; earlier ruling by Federal District Court, in suit brought by pharmaceutical industry, found program violates federal Medicaid statute and constitutional proscription against state interference with interstate commerce; other states are following Maine case closely; 29 states filed Supreme Court brief on Maine's behalf; about half the states have started experimenting with ways to hold down costs for various groups of consumers; photo (M)", "print_page": "1", "word_count": 952, "_id": "4fd28f618eb7c8105d866997", "snippet": "Maine's innovative effort to reduce prescription drug costs for uninsured state residents by pressuring manufacturers to grant price rebates received the Supreme Court's qualified approval today.    The 6-to-3 decision lifted an injunction that has...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/05/20/us/the-supreme-court-the-ruling-justices-allow-drug-cost-plan-to-go-forward.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "glocations", "value": "MAINE"}, {"name": "organizations", "value": "SUPREME COURT"}, {"name": "subject", "value": "STATES (US)"}, {"name": "subject", "value": "HEALTH INSURANCE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MEDICAID"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "DECISIONS AND VERDICTS"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Linda", "lastname": "GREENHOUSE"}], "original": "By LINDA GREENHOUSE"}, "document_type": "article", "pub_date": "2003-05-20T00:00:00Z", "section_name": "Front Page; Health; U.S."}, {"type_of_material": "Summary", "blog": [], "news_desk": "Metropolitan Desk", "lead_paragraph": "INTERNATIONAL A3-13 Bomber Kills 3 in Israel In a Blow to Peace Effort In the fifth attack against Israelis in less than 48 hours, a Palestinian suicide bomber detonated a shrapnel-packed bomb outside a mall in Afula, killing a security guard and two bystanders and delivering a new blow to a peace process that was already reeling. A1 Israel's forensic laboratory confirmed that a body found off a Tel Aviv beach was that of a Briton thought to have been involved in the April 30 nightclub attack that killed three people, the first suicide bombing to have been carried out by a non-Palestinian. A13", "headline": {"main": "NEWS SUMMARY"}, "abstract": null, "print_page": "2", "word_count": 1048, "_id": "4fd242918eb7c8105d7db838", "snippet": "INTERNATIONAL   A3-13    Bomber Kills 3 in Israel In a Blow to Peace Effort  In the fifth attack against Israelis in less than 48 hours, a Palestinian suicide bomber detonated a shrapnel-packed bomb outside a mall in Afula, killing a security guard...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/05/20/nyregion/news-summary-763519.html", "multimedia": [], "subsection_name": null, "keywords": [], "byline": null, "document_type": "article", "pub_date": "2003-05-20T00:00:00Z", "section_name": "New York and Region"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "They were billed as near wonder drugs, much safer and more effective in treating schizophrenia than anything that had come before. For many years, it seemed that the excitement was fully warranted.", "headline": {"main": "Leading Drugs for Psychosis Come Under New Scrutiny"}, "abstract": "Researchers suggest that new generation of antipsychotic drugs, called atypicals, may not be as effective as first thought when they were introduced 14 years ago, and may have dangerous side effects; studies find their superiority is at best modest, specific to certain symptoms and variable from drug to drug; there is increasing suspicion that they may cause serious side effects, notably diabetes, in some cases leading to death; issue of risks has become more pressing as drugs are prescribed for children and for adults with milder conditions; experts say drugs' benefits must be balanced by side effects and cost; more than 15 million prescriptions were written last year for Zyprexa and Risperdal, two leading drugs; when first introduced, they appeared so successful in treating psychotic illness that doctors began prescribing them for other conditions, including nonpsychotic depression, conduct disorder and severe aggression in children; detailed look at drugs' growth since 1990; photo; graphs; charts (L)", "print_page": "1", "word_count": 3220, "_id": "4fd242918eb7c8105d7db835", "snippet": "They were billed as near wonder drugs, much safer and more effective in treating schizophrenia than anything that had come before.    For many years, it seemed that the excitement was fully warranted.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/05/20/us/leading-drugs-for-psychosis-come-under-new-scrutiny.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "AGGRESSION"}, {"name": "subject", "value": "DIABETES"}, {"name": "subject", "value": "RISPERDAL (DRUG)"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CHILDREN AND YOUTH"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "ZYPREXA (DRUG)"}, {"name": "subject", "value": "DOCTORS"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "DEPRESSION (MENTAL)"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Erica", "lastname": "GOODE"}], "original": "By ERICA GOODE"}, "document_type": "article", "pub_date": "2003-05-20T00:00:00Z", "section_name": "Front Page; Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Enriched and emboldened after successful fights against asbestos and tobacco companies, some of the nation's top plaintiffs' lawyers have trained their sights on drug makers, claiming that many giant pharmaceutical companies have hidden the dangers of medicines the lawyers say have harmed thousands of people. In some cases the drugs at issue have already been pulled off the market, like Rezulin, a diabetes treatment from Pfizer that the Food and Drug Administration has linked to liver damage and is the target of almost 9,000 suits. Other suits name some of the industry's current best sellers, including Paxil, an antidepressant that plaintiffs contend is addictive -- a claim denied by the drug's maker, GlaxoSmithKline.", "headline": {"main": "Trial Lawyers Are Now Focusing On Lawsuits Against Drug Makers"}, "abstract": "Some of nation's top plaintiffs' lawyers are focuing on giant drug makers they claim have hidden dangers of medicines that have harmed thousands of people; some suits target drugs that have already been pulled off market, while others involve current best sellers; teams of lawyers are spending several million dollars preparing some cases for trial in hopes of winning billions of dollars; say Food and Drug Administration has systemically failed to protect patients from dangerous drugs; some drug development experts say juries may be ill-equipped to make complicated cost-benefit analysis FDA performs when it approves drug; companies have begun to consider threat of suits when deciding which drugs to pursue; table of suits; photo (M)", "print_page": "1", "word_count": 1727, "_id": "4fd22c088eb7c8105d7b7dba", "snippet": "Enriched and emboldened after successful fights against asbestos and tobacco companies, some of the nation's top plaintiffs' lawyers have trained their sights on drug makers, claiming that many giant pharmaceutical companies have hidden the dangers...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/05/18/us/trial-lawyers-are-now-focusing-on-lawsuits-against-drug-makers.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}, {"name": "subject", "value": "RECALLS AND BANS OF PRODUCTS"}, {"name": "subject", "value": "LIABILITY FOR PRODUCTS"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Alex", "lastname": "BERENSON"}], "original": "By ALEX BERENSON"}, "document_type": "article", "pub_date": "2003-05-18T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "The Senate Thursday night approved a sweeping tax cut bill that would reduce then suspend taxes on stock dividends before restoring them in 2007, adopting at least for now the central element of President Bush's tax plan. Vice President Dick Cheney cast a vote breaking a 50-50 tie on the dividend measure. Several hours later, the bill was approved 51 to 49 when a Democrat who had voted against the dividend aspect, Evan Bayh of Indiana, voted for the overall bill.", "headline": {"main": "Senate Adopts A Tax Cut Plan Of $350 Billion"}, "abstract": "Senate approves sweeping tax cut bill that reduces and then suspends taxes on stock dividends, and then restores them in 2007; seemingly temporary adoption of central element of Pres Bush's tax plan is passed after Vice Pres Dick Cheney casts tie-breaking vote on measure; later, bill is approved 51 to 49 when Sen Evan Bayh, Democrat who voted against dividend aspect, votes for overall bill; bill now moves to conference with House, which has passed substantially larger and different tax cut package; Bush wants to eliminate tax on dividends for full 10-year period covered by legislation, but to keep total cost of bill within $350 billion limit set by budget Senate adopted, dividend taxes would be fully reinstated in 2007; bill's sponsors express confidence that once taxes are off books they would never be allowed to reappear; Bush praises bill; Democrats ridicule temporary suspension as irresponsible gimmick; photo; chart comparing and contrasting Senate and House tax-cut bills (L)", "print_page": "1", "word_count": 1193, "_id": "4fd22b828eb7c8105d7b70be", "snippet": "The Senate Thursday night approved a sweeping tax cut bill that would reduce then suspend taxes on stock dividends before restoring them in 2007, adopting at least for now the central element of President Bush's tax plan.    Vice President Dick...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/05/16/us/senate-adopts-a-tax-cut-plan-of-350-billion.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "BUSH, GEORGE W"}, {"name": "persons", "value": "BAYH, EVAN"}, {"name": "persons", "value": "CHENEY, DICK"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "subject", "value": "TAXATION"}, {"name": "subject", "value": "LAW AND LEGISLATION"}, {"name": "subject", "value": "STOCKS AND BONDS"}], "byline": {"person": [{"firstname": "David", "middlename": "E.", "lastname": "ROSENBAUM", "rank": 1, "role": "reported", "organization": ""}], "original": "By DAVID E. ROSENBAUM"}, "document_type": "article", "pub_date": "2003-05-16T00:00:00Z", "section_name": "Front Page; U.S."}, {"type_of_material": "Op-Ed", "blog": [], "news_desk": "Editorial Desk", "lead_paragraph": "I never thought I'd say this, but I'm thinking of leaving New York for a city that's free and tolerant and treats me like an adult. Berlin, maybe, or Barcelona, or even London, the city I left nearly 20 years ago. I came to live in New York to be a musician and a bohemian, but the last time my band played in the city, in April, there were no fewer than five ''No Smoking'' signs in our dressing room. Two weeks later in Hamburg, Germany, our dressing room had five ashtrays. You can guess where we felt more welcome.", "headline": {"main": "Want to Smoke? Go to Hamburg"}, "abstract": "Joe Jackson Op-Ed article says anti-smoking and other cumbersome regulations have strangled New York City's nightlife and led him to pack his bags for more bohemian-friendly place, perhaps even London, city he left nearly twenty years ago (M)", "print_page": "27", "word_count": 803, "_id": "4fd270d68eb7c8105d82c8d0", "snippet": "I never thought I'd say this, but I'm thinking of leaving New York for a city that's free and tolerant and treats me like an adult. Berlin, maybe, or Barcelona, or even London, the city I left nearly 20 years ago.     I came to live in New York to be...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/05/16/opinion/want-to-smoke-go-to-hamburg.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "glocations", "value": "NEW YORK CITY"}, {"name": "glocations", "value": "LONDON (ENG)"}, {"name": "subject", "value": "SOCIAL CONDITIONS AND TRENDS"}, {"name": "subject", "value": "LIFE STYLES"}, {"name": "subject", "value": "LAW AND LEGISLATION"}, {"name": "subject", "value": "SMOKING AND TOBACCO"}, {"name": "subject", "value": "NIGHTCLUBS AND CABARETS"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Joe", "lastname": "Jackson"}], "original": "By Joe Jackson"}, "document_type": "article", "pub_date": "2003-05-16T00:00:00Z", "section_name": "Opinion"}], "meta": {"hits": 6, "offset": 0, "time": 35}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}